University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

Vogelzang, NJ, Beer, TM, Bartunkova, J, Kuklk, R, Miller, K, Oh, WK, Oudard, S, Pandha, HS, Sartor, AO, Spisek, R , Borgstein, NG and Gerritsen, WR (2015) Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 2015-05-29 - 2015-06-02, Chicago, IL.

Full text not available from this repository.
Item Type: Conference or Workshop Item (UNSPECIFIED)
Authors :
NameEmailORCID
Vogelzang, NJ
Beer, TM
Bartunkova, J
Kuklk, R
Miller, K
Oh, WK
Oudard, S
Pandha, HSh.pandha@surrey.ac.uk
Sartor, AO
Spisek, R
Borgstein, NG
Gerritsen, WR
Date : 20 May 2015
Contributors :
ContributionNameEmailORCID
publisherAMER SOC CLINICAL ONCOLOGY,
Uncontrolled Keywords : Science & Technology, Life Sciences & Biomedicine, Oncology
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:36
Last Modified : 17 May 2017 14:51
URI: http://epubs.surrey.ac.uk/id/eprint/828468

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800